Bulletin
Investor Alert

Market Pulse Archives

July 12, 2021, 7:44 a.m. EDT

Celldex's stock jumps on positive data from early-stage, open-label clinical trial for hives treatments

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Celldex Therapeutics Inc. (CLDX)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Celldex Therapeutics Inc. /zigman2/quotes/200895050/composite CLDX +1.82% soared 43.1% in premarket trading on Monday after the company shared positive data from an ongoing, open-label Phase 1b clinical trial for an experimental treatment for hives. Celldex said that 95% of participants diagnosed with two forms of chronic inducible urticaria reported a complete response to treatment and 5% had a partial response. The data was presented Friday during the European Academy of Allergy and Clinical Immunology Annual Congress. The study has 20 participants. The therapy is currently being tested intravenously but Celldex said it plans to begin testing a subcutaneous version of the drug in the third quarter. Celldex's stock has soared 84.9% this year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX -0.08% is up 16.3%.

/zigman2/quotes/200895050/composite
US : U.S.: Nasdaq
$ 52.10
+0.93 +1.82%
Volume: 412,555
Sept. 21, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$2.38 billion
Rev. per Employee
$59,344
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,354.19
-3.54 -0.08%
Volume: 1.91B
Sept. 21, 2021 5:12p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.